MC
AGIO icon

Maverick Capital’s Agios Pharmaceuticals AGIO Stock Holding History

Maverick Capital’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-26,960
Closed -$1.24M – 322
2021
Q3 		$1.24M Buy
+26,960
New +$1.3M 0.01% 246
2021
Q2 		– Sell
-4,042
Closed -$209K – 668
2021
Q1 		$209K Buy
4,042
+3,747
+1,270% +$186K ﹤0.01% 492
2020
Q4 		$13K Buy
+295
New +$11.7K ﹤0.01% 659

Other funds holding AGIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

Maverick Capital's AGIO Position: Q4 2021 in Review

Maverick Capital sold out of Agios Pharmaceuticals (AGIO) in Q4 2021, closing a stake of 26,960 shares — an estimated $1.24M sold.

Maverick Capital first reported a position in AGIO in Q4 2020 and held it in 3 quarters. The position peaked at $1.24M in Q3 2021. 161 funds tracked by Wall St. Rank hold AGIO as of Q4 2021.

  • Maverick Capital reported no remaining Agios Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Maverick Capital sold 26,960 Agios Pharmaceuticals shares in Q4 2021, an estimated $1.24M.
  • Maverick Capital first reported a position in Agios Pharmaceuticals in Q4 2020 and held it in 3 quarters.
  • Maverick Capital's Agios Pharmaceuticals position peaked at $1.24M in Q3 2021.
  • 161 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q4 2021.

Based on Maverick Capital's 13F filing for Q4 2021, filed 14 Feb 2022.